Symposium „Brustkrebs-Screening 2.0: Personalisiert – Prädiktiv – Präventiv-Partizipatorisch?“

Anne Quante; Marion Kiechle

doi:10.1055/s-0043-116475

Geburtshilfe und Frauenheilkunde, Table of Contents

Geburtshilfe Frauenheilkd 2017; 77(09): 960-962
DOI: 10.1055/s-0043-116475

GebFra Magazin

Aktuell diskutiert

Georg Thieme Verlag KG Stuttgart · New York

Symposium „Brustkrebs-Screening 2.0: Personalisiert – Prädiktiv – Präventiv-Partizipatorisch?“

Authors

Anne Quante
Marion Kiechle

Abstract

Full Text

References

Literatur
1 Robert Koch-Institut. Brustkrebs (Mammakarzinom). Online: http://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Brustkrebs/brustkrebs_node.html Stand: 06.07.2017
2 Gøtzsche P, Jørgensen K. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2013; (06) CD001877
3 Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 2012; 380: 1778-1786
4 Lauby-Secretan B, Scoccianti C, Loomis D. et al. Breast-cancer screening–viewpoint of the IARC Working Group. N Engl J Med 2015; 372: 2353-2358
5 Quante AS, Whittemore AS, Shriver T. et al. Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Res 2012; 14: R144
6 (G-BA) Gemeinsamer Bundesausschuss. Richtlinie des Gemeinsamen Bundesausschusses über die Früherkennung von Krebserkrankungen (Krebsfrüherkennungs-Richtlinie/KFE-RL). In der Fassung vom 18. Juni 2009, veröffentlicht im Bundesanzeiger 2009, Nr. 148a, zuletzt geändert am 24. Juli 2014, veröffentlicht im Bundesanzeiger AT 31.12.2014 B4, in Kraft getreten am 01. Jan. 2015.
7 Wegwarth O, Gigerenzer G. “There is nothing to worry about”: gynecologistsʼ counseling on mammography. Patient Educ Couns 2011; 84: 251-256
8 Wegwarth O, Schwartz LM, Woloshin S. et al. Do physicians understand cancer screening statistics? A national survey of primary care physicians in the United States. Ann Intern Med 2012; 156: 340-349
9 Wegwarth O, Gigerenzer G. Less is more: overdiagnosis and overtreatment: evaluation of what physicians tell their patients about screening harms. JAMA Intern Med 2013; 173: 2086-2087
10 Kiechle M. Brustkrebsfrüherkennung. Onkologe 2016; 22: 550-557
11 Schreer I. Intensivierte Früherkennung bei Frauen mit genetischer Brustkrebsdisposition. Onkologe 2005; 21: 211-219
12 Maas P, Barrdahl M, Joshi AD. et al. Breast cancer risk from modifiable and nonmodifiable risk factors among white women in the United States. JAMA Oncol 2016; 2: 1295-1302
13 Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427
14 Boyd NF, Guo H, Martin LJ. et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007; 356: 227-236
15 Hamajima N, Hirose K, Tajima K. et al. Alcohol, tobacco and breast cancer–collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 2002; 87: 1234-1245
16 Pfeiffer RM, Park Y, Kreimer AR. et al. Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies. PLoS Med 2013; 10: e1001492
17 Pfeiffer RM. Extensions of criteria for evaluating risk prediction models for public health applications. Biostatistics 2013; 14: 366-381
18 Engel C, Zachariae S, Fischer C. Familiärer Brustkrebs – empirische Erkrankungsrisiken und Risikoberechnungsmodelle. medgen 2015; 27: 217-222
19 Fischer C, Engel C, Sutter C. et al. BRCA1/2 testing: uptake, phenocopies, and strategies to improve detection rates in initially negative families. Clin Genet 2012; 82: 478-483